The emerging spectrum of allelic variation in schizophrenia: Current evidence and strategies for the identification and functional characterization of common and rare variants

Molecular Psychiatry

Volumn 18, Issue 1, 2013, Pages 38-52

  Mowry, B J ^a   Gratten, J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

CNV; functional genomics; GWAS; schizophrenia; sequencing; SNP

Indexed keywords

ALLELE; CHROMOSOME DELETION; CHROMOSOME DUPLICATION; COPY NUMBER VARIATION; COST EFFECTIVENESS ANALYSIS; CYTOGENETICS; FUNCTIONAL GENOMICS; GENE DELETION; GENE EXPRESSION; GENE FREQUENCY; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HIGH THROUGHPUT SCREENING; HUMAN; META ANALYSIS (TOPIC); MISSENSE MUTATION; NERVE CELL DIFFERENTIATION; NONHUMAN; NONSENSE MUTATION; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; RISK ASSESSMENT; SAMPLE SIZE; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; WNT SIGNALING PATHWAY;

GENETIC LINKAGE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOME, HUMAN; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; SCHIZOPHRENIA;

EID: 84871267120     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2012.34     Document Type: Review

References (215)

1. Sorensen HJ, Mortensen EL, Schiffman J, Reinisch JM, Maeda J, Mednick SA. Early developmental milestones and risk of schizophrenia: A 45-year follow-up of theCopenhagen Perinatal Cohort. Schizophrenia Res 2010; 118: 41-47.
2. Woodberry KA, Giuliano AJ, Seidman LJ. Premorbid IQ in schizophrenia: A metaanalytic review. Am J Psychiatry 2008; 165: 579-587.
3. McGorry PD, Yung AR, Bechdolf A, Amminger P. Back to the future: predicting and reshaping the course of psychotic disorder. Arch Gen Psychiatry 2008; 65: 25-27.
4. Bleuler E. Dementia Praecox or the Group of Schizophrenias (1911). International Universities Press: New York, 1950.
5. Carpenter Jr. WT, Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 1988; 145: 578-583.
6. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-796.
7. Craddock N, Donovan MC, Owen MJ. Psychosis genetics: Modeling the relationship between schizophrenia, bipolar disorder, and mixed (or 00schizoaffective00) psychoses. Schizophr Bull 2009; 35: 482-490.
8. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med 2005; 2: e141.
9. Alaraisanen A, Miettunen J, Rasanen P, Fenton W, Koivumaa-Honkanen HT, Isohanni M. Suicide rate in schizophrenia in the Northern Finland 1966 Birth Cohort. Social Psychiatry Psychiatric Epidemiol 2009; 44: 1107-1110.
10. Robinson DG, Woerner MG, McMeniman M, Mendelowitz A, Bilder RM. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 2004; 161: 473-479.
11. Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J et al. Recovery from psychotic illness: A 15- and 25-year international follow-up study. Br J Psychiatry J Mental Sci 2001; 178: 506-517.
12. Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011; 21: 718-779.
13. Marwaha S, Johnson S, Bebbington P, Stafford M, Angermeyer MC, Brugha T et al. Rates and correlates of employment in people with schizophrenia in the UK, France and Germany. Br J Psychiatry J Mental Sci 2007; 191: 30-37.
14. Folsom DP, Hawthorne W, Lindamer L, Gilmer T, Bailey A, Golshan S et al. Prevalence and risk factors for homelessness and utilization of mental health services among 10 340 patients with serious mental illness in a large public mental health system. Am J Psychiatry 2005; 162: 370-376.
15. WHO. The Global Burden of Disease: 2004 Update. WHO Press: Geneva, Switzerland, 2008.
16. Feinberg I. Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence? J Psychiatr Res 1982; 17: 319-334.
17. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987; 44: 660-669.
18. Murray RM, Jones P, Callaghan E. Fetal brain development and later schizophrenia. Ciba Found Symp 1991; 156: 155-163, discussion 163-170.
19. van Os J, Kenis G, Rutten BP. The environment and schizophrenia. Nature 2010; 468: 203-212.
20. Sullivan PF. The genetics of schizophrenia. PLoS Med 2005; 2: e212.
21. Kraepelin E. Dementia Præcox and Paraphrenia. Chicago Medical Book Company: Chicago, 1919.
22. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 2003; 60: 1187-1192.
23. Cardno AG, Gottesman. Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics. Am J Med Genet 2000; 97: 12-17.
24. Karayiorgou M, Simon TJ, Gogos JA. 22q11.2 microdeletions: linking DNA structural variation to brain dysfunction and schizophrenia. Nat Rev Neurosci 2010; 11: 402-416.
25. Kobrynski LJ, Sullivan KE. Velocardiofacial syndrome, DiGeorge syndrome: the chromosome 22q11.2 deletion syndromes. Lancet 2007; 370: 1443-1452.
26. Shprintzen RJ, Goldberg RB, Lewin ML, Sidoti EJ, Berkman MD, Argamaso RV et al. A new syndrome involving cleft palate, cardiac anomalies, typical facies, and learning disabilities: velo-cardio-facial syndrome. Cleft Palate J 1978; 15: 56-62.
27. Murphy KC, Jones LA, Owen MJ. High rates of schizophrenia in adults with velocardio- facial syndrome. Arch Gen Psychiatry 1999; 56: 940-945.
28. Pulver AE, Nestadt G, Goldberg R, Shprintzen RJ, Lamacz M, Wolyniec PS et al. Psychotic illness in patients diagnosed with velo-cardio-facial syndrome and their relatives. J Nerv Ment Dis 1994; 182: 476-478.
29. Bassett AS, Hodgkinson K, Chow EW, Correia S, Scutt LE, Weksberg R. 22q11 deletion syndrome in adults with schizophrenia. Am J Med Genet 1998; 81: 328-337.
30. Karayiorgou M, Morris MA, Morrow B, Shprintzen RJ, Goldberg R, Borrow J et al. Schizophrenia susceptibility associated with interstitial deletions of chromosome22q11. Proc Natl Acad Sci USA 1995; 92: 7612-7616.
31. Bassett AS, Chow EW, AbdelMalik P, Gheorghiu M, Husted J, Weksberg R. Theschizophrenia phenotype in 22q11 deletion syndrome. Am J Psychiatry 2003;160: 1580-1586.
32. Millar JK, Wilson-Annan JC, Anderson S, Christie S, Taylor MS, Semple CA et al. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum Mol Genet 2000; 9: 1415-1423.
33. Jacobs PA, Brunton M, Frackiewicz A, Newton MPJLC, Robson EB. Studies on afamily with three cytogenetic markers. Ann Hum Genet 1970; 33: 325-336.
34. St Clair D, Blackwood D, Muir W, Carothers A, Walker M, Spowart G et al. Association within a family of a balanced autosomal translocation with major mental illness. Lancet 1990; 336: 13-16.
35. Blackwood DH, Fordyce A, Walker MT, St Clair DM, Porteous DJ, Muir WJ. Schizophrenia and affective disorders-cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family. Am J Hum Genet 2001; 69: 428-433.
36. Ishizuka K, Kamiya A, Oh EC, Kanki H, Seshadri S, Robinson JF et al. DISC1- dependent switch from progenitor proliferation to migration in the developing cortex. Nature 2011; 473: 92-96.
37. Sanders AR, Duan J, Levinson DF, Shi J, He D, Hou C et al. No significant association of 14 candidate genes with schizophrenia in a large European ancestry sample: implications for psychiatric genetics. Am J Psychiatry 2008; 165: 497-506.
38. Collins AL, Kim Y, Sklar P, Donovan MC, Sullivan PF. Hypothesis-driven candidate genes for schizophrenia compared to genome-wide association results. Psychological Med 2011; 42: 1-10.
39. Paunio T, Ekelund J, Varilo T, Parker A, Hovatta I, Turunen JA et al. Genome-wide scan in a nationwide study sample of schizophrenia families in Finland reveals susceptibility loci on chromosomes 2q and 5q. Hum Mol Genet 2001; 10: 3037-3048.
40. Maziade M, Roy MA, Chagnon YC, Cliche D, Fournier JP, Montgrain N et al. Shared and specific susceptibility loci for schizophrenia and bipolar disorder: A dense genome scan in Eastern Quebec families. Mol Psychiatry 2005; 10: 486-499.
41. Holliday EG, Nyholt DR, Tirupati S, John S, Ramachandran P, Ramamurti M et al.Strong evidence for a novel schizophrenia risk locus on chromosome 1p31.1 in homogeneous pedigrees from Tamil Nadu, India. Am J Psychiatry 2009; 166: 206-215.
42. Holmans PA, Riley B, Pulver AE, Owen MJ, Wildenauer DB, Gejman PV et al. Genomewide linkage scan of schizophrenia in a large multicenter pedigree sample using single nucleotide polymorphisms. Mol Psychiatry 2009; 14: 786-795.
43. Ng MY, Levinson DF, Faraone SV, Suarez BK, DeLisi LE, Arinami T et al. Metaanalysis of 32 genome-wide linkage studies of schizophrenia. Mol Psychiatry 2009; 14: 774-785.
44. Allen NC, Bagade S, McQueen MB, Ioannidis JPA, Kavvoura FK, Khoury MJ et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet 2008; 40: 827-834.
45. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, Collins FS et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci USA 2009; 106: 9362-9367.
46. Visscher PM, Brown MA, McCarthy MI, Yang J. Five years of GWAS discovery. Am J Human Genet 2012; 90: 7-24.
47. Mah S, Nelson MR, Delisi LE, Reneland RH, Markward N, James MR et al. Identification of the semaphorin receptor PLXNA2 as a candidate for susceptibility to schizophrenia. Mol Psychiatry 2006; 11: 471-478.
48. Lencz T, Morgan TV, Athanasiou M, Dain B, Reed CR, Kane JM et al. Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. Mol Psychiatry 2007; 12: 572-580.
49. Sullivan PF, Lin D, Tzeng JY, van den Oord E, Perkins D, Stroup TS et al. Genomewide association for schizophrenia in the CATIE study: results of stage 1. Mol Psychiatry 2008; 13: 570-584.
50. Kirov G, Zaharieva I, Georgieva L, Moskvina V, Nikolov I, Cichon S et al. A genome-wide association study in 574 schizophrenia trios using DNA pooling. Mol Psychiatry 2009; 14: 796-803.
51. Liu Y, Chen G, Norton N, Liu W, Zhu H, Zhou P et al. Whole genome association study in a homogenous population in Shandong peninsula of China revealsJARID2 as a susceptibility gene for schizophrenia. J Biomed Biotechnol 2009; 2009: 536918.
52. Need AC, Ge D, Weale ME, Maia J, Feng S, Heinzen EL et al. A genomewide investigation of SNPs and CNVs in schizophrenia. PLoS Genet 2009; 5: e1000373.
53. Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009; 460: 748-752.
54. Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, Pe0er I et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 2009; 460: 753-757.
55. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D et al. Common variants conferring risk of schizophrenia. Nature 2009; 460: 744-747.
56. Rietschel M, Mattheisen M, Degenhardt F, Kahn RS, Linszen DH, Os JV et al. Association between genetic variation in a region on chromosome 11 and schizophrenia in large samples from Europe. Mol Psychiatry advance online publication, 12 July 2011; doi:10.1038/mp.2011.80.
57. Ripke S, Sanders AR, Kendler KS, Levinson DF, Sklar P, Holmans PA et al. Genomewide association study identifies five new schizophrenia loci. Nat Genet 2011; 43: 969-976.
58. Shi Y, Li Z, Xu Q, Wang T, Li T, Shen J et al. Common variants on 8p12 and 1q24.2 confer risk of schizophrenia. Nat Genet 2011; 43: 1224-1227.
59. Steinberg S, de Jong S, Andreassen OA, Werge T, Borglum AD, Mors O et al. Common variants at VRK2 and TCF4 conferring risk of schizophrenia. Human Mol Genet 2011; 20: 4076-4081.
60. Yue W-H, Wang H-F, Sun L-D, Tang F-L, Liu Z-H, Zhang H-X et al. Genome-wide association study identifies a susceptibility locus for schizophrenia in Han Chinese at 11p11.2. Nat Genet 2011; 43: 1228-1231.
61. O'Donovan MC, Craddock N, Norton N, Williams H, Peirce T, Moskvina V et al. Identification of loci associated with schizophrenia by genome-wide associationand follow-up. Nat Genet 2008; 40: 1053-1055.
62. Smrt RD, Szulwach KE, Pfeiffer RL, Li X, Guo W, Pathania M et al. MicroRNA miR- 137 regulates neuronal maturation by targeting ubiquitin ligase mind bomb-1. Stem Cells 2010; 28: 1060-1070.
63. Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, Yu M et al. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med 2008; 6: 14.
64. Ikeda M, Aleksic B, Kinoshita Y, Okochi T, Kawashima K, Kushima I et al. Genomewide association study of schizophrenia in a Japanese population. Biol Psychiatry 2011; 69: 472-478.
65. Visscher PM, Goddard ME, Derks EM, Wray NR. Evidence-based psychiatricgenetics, AKA the false dichotomy between common and rare variant hypotheses. Mol Psychiatry advance online publication, 14 June 2011; doi:10.1038/mp.2011.65.
66. Craddock N, O'Donovan MC, Owen MJ. Phenotypic and genetic complexity of psychosis. Invited commentary on Schizophrenia: A common disease caused by multiple rare alleles. Br J Psychiatry 2007; 190: 200-203.
67. McClellan JM, Susser E, King M-C. Schizophrenia: A common disease caused by multiple rare alleles. Br J Psychiatry 2007; 190: 194-199.
68. Ruderfer DM, Kirov G, Chambert K, Moran JL, Owen MJ, O'Donovan MC et al. A family-based study of common polygenic variation and risk of schizophrenia. Mol Psychiatry 2011; 16: 887-888.
69. Mitchell KJ, Porteous DJ. Rethinking the genetic architecture of schizophrenia.Psychol Med 2010; 41: 1-14.
70. Dickson SP, Wang K, Krantz I, Hakonarson H, Goldstein DB. Rare variants create synthetic genome-wide associations. PLoS Biol 2010; 8: e1000294.
71. Anderson CA, Soranzo N, Zeggini E, Barrett JC. Synthetic associations are unlikely to account for many common disease genome-wide association signals. PLoS Biol 2011; 9: e1000580.
72. Wray NR, Purcell SM, Visscher PM. Synthetic associations created by rare variants do not explain most GWAS results. PLoS Biol 2011; 9: e1000579.
73. Lee SH, DeCandia TR, Ripke S, Yang J, The Schizophrenia Psychiatric GenomeWide Association Study Consortium (PGC-SCZ), The International Schizophrenia Consortium (ISC) et al. Estimating the proportion of variation in susceptibility toschizophrenia captured by common SNPs. Nat Genet 2012; 44: 247-250.
74. Yang J, Benyamin B, McEvoy BP, Gordon S, Henders AK, Nyholt DR et al. Common SNPs explain a large proportion of the heritability for human height. Nat Genet 2010; 42: 565-569.
75. Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, Cooper GM et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 2008; 320: 539-543.
76. Stone JL, O'Donovan MC, Gurling H, Kirov GK, Blackwood DHR, Corvin A et al. Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature 2008; 455: 237-241.
77. Levinson DF, Duan J, Oh S, Wang K, Sanders AR, Shi J et al. Copy number variants in schizophrenia: confirmation of five previous findings and new evidence for 3q29 Microdeletions and VIPR2 Duplications. Am J Psychiatry 2011; 168: 302-316.
78. Malhotra D, McCarthy S, Michaelson JJ, Vacic V, Burdick KE, Yoon S et al. High frequencies of De Novo CNVs in bipolar disorder and schizophrenia. Neuron 2011; 72: 951-963.
79. Xu B, Roos JL, Levy S, Van Rensburg EJ, Gogos JA, Karayiorgou M. Strong association of de novo copy number mutations with sporadic schizophrenia. Nat Genet 2008; 40: 880-885.
80. Kirov G, Pocklington AJ, Holmans P, Ivanov D, Ikeda M, Ruderfer D et al. De novo CNV analysis implicates specific abnormalities of postsynaptic signaling complexes in the pathogenesis of schizophrenia. Mol Psychiatry 2012; 17: 142-153.
81. Stefansson H, Rujescu D, Cichon S, Pietilainen OPH, Ingason A, Steinberg S et al. Large recurrent microdeletions associated with schizophrenia. Nature 2008; 455: 232-236.
82. Kirov G, Rujescu D, Ingason A, Collier DA, O'Donovan MC, Owen MJ. Neurexin 1 (NRXN1) deletions in schizophrenia. Schizophr Bull 2009; 35: 851-854.
83. McCarthy SE, Makarov V, Kirov G, Addington AM, McClellan J, Yoon S et al. Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet 2009; 41: 1223-1227.
84. Rujescu D, Ingason A, Cichon S, Pietilainen OPH, Barnes MR, Toulopoulou T et al. Disruption of the neurexin 1 gene is associated with schizophrenia. Hum Mol Genet 2009; 18: 988-996.
85. Ingason A, Rujescu D, Cichon S, Sigurdsson E, Sigmundsson T, Pietilainen OP et al. Copy number variations of chromosome 16p13.1 region associated with schizophrenia. Mol Psychiatry 2011; 16: 17-25.
86. Vacic V, McCarthy S, Malhotra D, Murray F, Chou H-H, Peoples A et al.Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia. Nature 2011; 471: 499-503.
87. Rees E, Moskvina V, Owen MJ, O'Donovan MC, Kirov G. De novo rates and selection of schizophrenia-associated copy number variants. Biol Psychiatry 2011; 70: 1109-1114.
88. Haukka J, Suvisaari J, Lonnqvist J. Fertility of patients with schizophrenia, their siblings, and the general population: A cohort study from 1950 to 1959 in Finland. Am J Psychiatry 2003; 160: 460-463.
89. Melhem N, Middleton F, McFadden K, Klei L, Faraone SV, Vinogradov S et al. Copy number variants for schizophrenia and related psychotic disorders in oceanic Palau: risk and transmission in extended pedigrees. Biol Psychiatry 2011; 70: 1115-1121.
90. Pinto D, Darvishi K, Shi X, Rajan D, Rigler D, Fitzgerald T et al. Comprehensive assessment of array-based platforms and calling algorithms for detection of copy number variants. Nat Biotechnol 2011; 29: 512-520.
91. Keller MC, Miller G. Resolving the paradox of common, harmful, heritable mental disorders: which evolutionary genetic models work best? Behav Brain Sci 2006;29: 385.
92. Durbin RM, Abecasis GR, Altshuler DL, Auton A, Brooks LD, Gibbs RA et al. A map of human genome variation from population-scale sequencing. Nature 2010;467: 1061-1073.
93. State MW, Levitt P. The conundrums of understanding genetic risks for autism spectrum disorders. Nat Neurosci 2011; 14: 1499-1506.
94. Girard SL, Gauthier J, Noreau A, Xiong L, Zhou S, Jouan L et al. Increased exonic de novo mutation rate in individuals with schizophrenia. Nat Genet 2011; 43: 860-863.
95. Xu B, Roos JL, Dexheimer P, Boone B, Plummer B, Levy S et al. Exome sequencing supports a de novo mutational paradigm for schizophrenia. Nat Genet 2011; 43: 864-868.
96. Addington AM, Gauthier J, Piton A, Hamdan FF, Raymond A, Gogtay N et al. A novel frameshift mutation in UPF3B identified in brothers affected with childhood onset schizophrenia and autism spectrum disorders. Mol Psychiatry 2011; 16: 238-239.
97. Awadalla P, Gauthier J, Myers RA, Casals F, Hamdan FF, Griffing AR et al. Direct measure of the de novo mutation rate in autism and schizophrenia cohorts. Am J Hum Genet 2010; 87: 316-324.
98. Carroll LS, Williams NM, Moskvina V, Russell E, Norton N, Williams HJ et al.Evidence for rare and common genetic risk variants for schizophrenia at protein kinase C, alpha. Mol Psychiatry 2010; 15: 1101-1111.
99. Frank RA, McRae AF, Pocklington AJ, van de Lagemaat LN, Navarro P, Croning MD et al. Clustered coding variants in the glutamate receptor complexes of individuals with schizophrenia and bipolar disorder. PLoS One 2011; 6: e19011.
100. Gauthier J, Champagne N, Lafreniere RG, Xiong L, Spiegelman D, Brustein E et al. De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia. Proc Natl Acad Sci USA 2010; 107: 7863-7868.
101. Knight HM, Pickard BS, Maclean A, Malloy MP, Soares DC, McRae AF et al. A cytogenetic abnormality and rare coding variants identify ABCA13 as a candidate gene in schizophrenia, bipolar disorder, and depression. Am J Hum Genet 2009; 85: 833-846.
102. Kushima I, Nakamura Y, Aleksic B, Ikeda M, Ito Y, Shiino T et al. Resequencing and association analysis of the KALRN and EPHB1 genes and their contribution to schizophrenia susceptibility. Schizophr Bull advance online publication, 1 November 2010; doi:10.1093/schbul/sbq118.
103. Piton A, Gauthier J, Hamdan FF, Lafreniere RG, Yang Y, Henrion E et al. Systematic resequencing of X-chromosome synaptic genes in autism spectrum disorder and schizophrenia. Mol Psychiatry 2011; 16: 867-880.
104. Tarabeux J, Champagne N, Brustein E, Hamdan FF, Gauthier J, Lapointe M et al. De novo truncating mutation in kinesin 17 associated with schizophrenia. Biol Psychiatry 2010; 68: 649-656.
105. Vermeesch JR, Balikova I, Schrander-Stumpel C, Fryns JP, Devriendt K. The causality of de novo copy number variants is overestimated. Eur J Hum Genet 2011; 19: 1112-1113.
106. Lichtenstein P, Yip BH, Bjork C, Pawitan Y, Cannon TD, Sullivan PF et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: A population-based study. Lancet 2009; 373: 234-239.
107. Gottesman II, Laursen TM, Bertelsen A, Mortensen PB. Severe mental disorders in offspring with 2 psychiatrically ill parents. Arch Gen Psychiatry 2010; 67: 252-257.
108. Moskvina V, Craddock N, Holmans P, Nikolov I, Pahwa JS, Green E et al. Genewide analyses of genome-wide association data sets: evidence for multiple common risk alleles for schizophrenia and bipolar disorder and for overlap in genetic risk. Mol Psychiatry 2009; 14: 252-260.
109. Williams HJ, Craddock N, Russo G, Hamshere ML, Moskvina V, Dwyer S et al. Most genome-wide significant susceptibility loci for schizophrenia and bipolardisorder reported to date cross-traditional diagnostic boundaries. Human Mol Genet 2011; 20: 387-391.
110. Williams HJ, Norton N, Dwyer S, Moskvina V, Nikolov I, Carroll L et al. Fine mapping of ZNF804A and genome-wide significant evidence for its involvement in schizophrenia and bipolar disorder. Mol Psychiatry 2011; 16: 429-441.
111. Sklar P, Ripke S, Scott LJ, Andreassen OA, Cichon S, Craddock N et al. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nat Genet 2011; 43: 977-983.
112. Glessner JT, Wang K, Cai G, Korvatska O, Kim CE, Wood S et al. Autism genomewide copy number variation reveals ubiquitin and neuronal genes. Nature 2009; 459: 569-573.
113. Mefford HC, Sharp AJ, Baker C, Itsara A, Jiang Z, Buysse K et al. Recurrent rearrangements of chromosome 1q21.1 and variable pediatric phenotypes. N Engl J Med 2008; 359: 1685-1699.
114. Quintero-Rivera F, Sharifi-Hannauer P, Martinez-Agosto JA. Autistic and psychiatric findings associated with the 3q29 microdeletion syndrome: casereport and review. Am J Med Genet A 2010; 152A: 2459-2467.
115. Sivakumaran S, Agakov F, Theodoratou E, Prendergast JG, Zgaga L, Manolio T et al. Abundant pleiotropy in human complex diseases and traits. Am J Human Genet 2011; 89: 607-618.
116. Lango Allen H, Estrada K, Lettre G, Berndt SI, Weedon MN, Rivadeneira F et al.Hundreds of variants clustered in genomic loci and biological pathways affecthuman height. Nature 2010; 467: 832-838.
117. Dushlaine C, Kenny E, Heron E, Donohoe G, Gill M, Morris D et al. Molecular pathways involved in neuronal cell adhesion and membrane scaffolding contribute to schizophrenia and bipolar disorder susceptibility. Mol Psychiatry 2010; 16: 286-292.
118. Lips ES, Cornelisse LN, Toonen RF, Min JL, Hultman CM, Holmans PA et al. Functional gene group analysis identifies synaptic gene groups as risk factor for schizophrenia. Mol Psychiatry advance online publication, 20 September 2011; doi:10.1038/mp.2011.117.
119. Glessner JT, Reilly MP, Kim CE, Takahashi N, Albano A, Hou C et al. Strong synaptic transmission impact by copy number variations in schizophrenia. Proc Natl Acad Sci USA 2010; 107: 10584-10589.
120. Raychaudhuri S, Korn JM, McCarroll SA, Consortium IS, Altshuler D, Sklar P et al. Accurately assessing the risk of schizophrenia conferred by rare copy-number variation affecting genes with brain function. PLoS Genet 2010; 6: e1001097; doi:10.1371/journal.pgen.1001097.
121. Kim Y, Zerwas S, Trace SE, Sullivan PF. Schizophrenia genetics: where next? Schizophrenia Bull 2011; 37: 456-463.
122. Pritchard JK. Are rare variants responsible for susceptibility to complex diseases? Am J Hum Genet 2001; 69: 124-137.
123. Eyre-Walker A. Evolution in health and medicine sackler colloquium: genetic architecture of a complex trait and its implications for fitness and genomewide association studies. Proc Natl Acad Sci USA 2010; 107(Suppl 1): 1752-1756.
124. Richards AL, Jones L, Moskvina V, Kirov G, Gejman PV, Levinson DF et al. Schizophrenia susceptibility alleles are enriched for alleles that affect gene expression in adult human brain. Mol Psychiatry 2011; 17: 193-201.
125. Sullivan P. Don0t give up on GWAS. Mol Psychiatry 2011; 17: 2-3.
126. Lee SH, Wray NR, Goddard ME, Visscher PM. Estimating missing heritability for disease from genome-wide association studies. Am J Human Genet 2011; 88: 294-305.
127. Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 2010; 42: 579-589.
128. Yang J, Wray NR, Visscher PM. Comparing apples and oranges: equating the power of case-control and quantitative trait association studies. Genet Epidemiol 2010; 34: 254-257.
129. Cortes A, Brown MA. Promise and pitfalls of the immunochip. Arthritis Res Ther 2011; 13: 101.
130. Trynka G, Hunt KA, Bockett NA, Romanos J, Mistry V, Szperl A et al. Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. Nat Genet 2011; 43: 1193-1201.
131. Mardis ER. A decade0s perspective on DNA sequencing technology. Nature 2011; 470: 198-203.
132. Bodmer W, Bonilla C. Common and rare variants in multifactorial susceptibility to common diseases. Nat Genet 2008; 40: 695-701.
133. Shendure J. Next-generation human genetics. Genome Biol 2011; 12: 408.
134. Bamshad MJ, Ng SB, Bigham AW, Tabor HK, Emond MJ, Nickerson DA et al.Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev Genet 2011; 12: 745-755.
135. Najmabadi H, Hu H, Garshasbi M, Zemojtel T, Abedini SS, Chen W et al. Deepsequencing reveals 50 novel genes for recessive cognitive disorders. Nature 2011; 478: 57-63.
136. Roach JC, Glusman G, Smit AF, Huff CD, Hubley R, Shannon PT et al. Analysis of genetic inheritance in a family quartet by whole-genome sequencing. Science 2010; 328: 636-639.
137. Li B, Leal SM. Discovery of rare variants via sequencing: implications for the design of complex trait association studies. PLoS Genet 2009; 5: e1000481.
138. Morris AP, Zeggini E. An evaluation of statistical approaches to rare variant analysis in genetic association studies. Genet Epidemiol 2010; 34: 188-193.
139. Sulem P, Gudbjartsson DF, Walters GB, Helgadottir HT, Helgason A, Gudjonsson SA et al. Identification of low-frequency variants associated with gout and serumuric acid levels. Nat Genet 2011; 43: 1127-1130.
140. Rivas MA, Beaudoin M, Gardet A, Stevens C, Sharma Y, Zhang CK et al. Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nat Genet 2011; 43: 1066-1073.
141. Raychaudhuri S, Iartchouk O, Chin K, Tan PL, Tai AK, Ripke S et al. A rare penetrant mutation in CFH confers high risk of age-related macular degeneration.Nat Genet 2011; 43: 1232-1236.
142. Bonnefond A, Clement N, Fawcett K, Yengo L, Vaillant E, Guillaume JL et al. Rare MTNR1B variants impairing melatonin receptor 1B function contribute to type 2 diabetes. Nat Genet 2012; 44: 297-301.
143. Yokoyama S, Woods SL, Boyle GM, Aoude LG, MacGregor S, Zismann V et al. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 2011; 480: 99-103.
144. Cooper GM, Shendure J. Needles in stacks of needles: finding disease-causal variants in a wealth of genomic data. Nat Rev Genet 2011; 12: 628-640.
145. Ozsolak F, Milos PM. RNA sequencing: Advances, challenges and opportunities. Nat Rev Genet 2011; 12: 87-98.
146. Kang HJ, Kawasawa YI, Cheng F, Zhu Y, Xu X, Li M et al. Spatio-temporal transcriptome of the human brain. Nature 2011; 478: 483-489.
147. Colantuoni C, Lipska BK, Ye T, Hyde TM, Tao R, Leek JT et al. Temporal dynamics and genetic control of transcription in the human prefrontal cortex. Nature 2011; 478: 519-523.
148. Werner T. Next generation sequencing in functional genomics. Brief Bioinform 2010; 11: 499-511.
149. Ala-Korpela M, Kangas AJ, Inouye M. Genome-wide association studies and systems biology: together at last. Trends Genet 2011; 27: 493-498.
150. Dempster EL, Pidsley R, Schalkwyk LC, Owens S, Georgiades A, Kane F et al.Disease-associated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder. Hum Mol Genet 2011; 20: 4786-4796.
151. Mudge J, Miller NA, Khrebtukova I, Lindquist IE, May GD, Huntley JJ et al. Genomic convergence analysis of schizophrenia: MRNA sequencing reveals altered synaptic vesicular transport in post-mortem cerebellum. PLoS One 2008; 3: e3625.
152. Rollins B, Martin MV, Morgan L, Vawter MP. Analysis of whole genome biomarker expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 919-936.
153. Goldsmith CA, Rogers DP. The case for autoimmunity in the etiology of schizophrenia. Pharmacotherapy 2008; 28: 730-741.
154. Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K et al. Potential metabolite markers of schizophrenia. Mol Psychiatry advance online publication, 25 October 2011; doi:10.1038/mp.2011.131.
155. Deep-Soboslay A, Benes FM, Haroutunian V, Ellis JK, Kleinman JE, Hyde TM. Psychiatric brain banking: three perspectives on current trends and future directions. Biol Psychiatry 2011; 69: 104-112.
156. Wu SM, Hochedlinger K. Harnessing the potential of induced pluripotent stem cells for regenerative medicine. Nat Cell Biol 2011; 13: 497-505.
157. Huttner A, Rakic P. Diagnosis in a dish: your skin can help your brain. Nat Med 2011; 17: 1558-1559.
158. Chiang CH, Su Y, Wen Z, Yoritomo N, Ross CA, Margolis RL et al. Integration-free induced pluripotent stem cells derived from schizophrenia patients with a DISC1 mutation. Mol Psychiatry 2011; 16: 358-360.
159. Brennand KJ, Simone A, Jou J, Gelboin-Burkhart C, Tran N, Sangar S et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature2011; 473: 221-225.
160. Pedrosa E, Sandler V, Shah A, Carroll R, Chang C, Rockowitz S et al. Development of patient-specific neurons in schizophrenia using induced pluripotent stemcells. J Neurogenet 2011; 25: 88-103.
161. Kvajo M, McKellar H, Gogos JA. Avoiding mouse traps in schizophrenia genetics: lessons and promises from current and emerging mouse models. Neuroscience advance online publication, 27 July 2011; doi:10.1016/j. neuroscience. 2011.07.051 (in press).
162. Merscher S, Funke B, Epstein JA, Heyer J, Puech A, Lu MM et al. TBX1 is responsible for cardiovascular defects in velo-cardio-facial/DiGeorge syndrome. Cell 2001; 104: 619-629.
163. Stark KL, Xu B, Bagchi A, Lai WS, Liu H, Hsu R et al. Altered brain microRNA biogenesis contributes to phenotypic deficits in a 22q11-deletion mouse model. Nat Genet 2008; 40: 751-760.
164. Burne T, Scott E, van Swinderen B, Hilliard M, Reinhard J, Claudianos C et al. Big ideas for small brains: what can psychiatry learn from worms, flies, bees and fish? Mol Psychiatry 2011; 16: 7-16.
165. van Alphen B, van Swinderen B. Drosophila strategies to study psychiatric disorders. Brain Res Bull advance online publication, 17 September 2011; doi:10.1016/j.brainresbull.2011.09.007 (in press).
166. Brennand KJ, Gage FH. Concise review: The promise of human induced pluripotent stem cell-based studies of schizophrenia. Stem Cells 2011; 29:1915-1922.
167. Dolmetsch R, Geschwind DH. The human brain in a dish: the promise of iPSCderived neurons. Cell 2011; 145: 831-834.
168. Dragunow M. The adult human brain in preclinical drug development. Nat Rev Drug Discovery 2008; 7: 659-666.
169. Rakic P. Evolution of the neocortex: A perspective from developmental biology. Nat Rev Neurosci 2009; 10: 724-735.
170. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003; 160: 636-645.
171. Meyer-Lindenberg A. From maps to mechanisms through neuroimaging ofschizophrenia. Nature 2010; 468: 194-202.
172. Greenwood TA, Braff DL, Light GA, Cadenhead KS, Calkins ME, Dobie DJ et al. Initial heritability analyses of endophenotypic measures for schizophrenia: the consortium on the genetics of schizophrenia. Arch Gen Psychiatry 2007; 64: 1242-1250.
173. Boos HB, Aleman A, Cahn W, Hulshoff Pol H, Kahn RS. Brain volumes in relatives of patients with schizophrenia: A meta-analysis. Arch Gen Psychiatry 2007; 64: 297-304.
174. Goldman AL, Pezawas L, Mattay VS, Fischl B, Verchinski BA, Zoltick B et al.Heritability of brain morphology related to schizophrenia: A large-scale automated magnetic resonance imaging segmentation study. Biol Psychiatry 2008; 63: 475-483.
175. Esslinger C, Walter H, Kirsch P, Erk S, Schnell K, Arnold C et al. Neural
176. Esslinger C, Kirsch P, Haddad L, Mier D, Sauer C, Erk S et al. Cognitive state and connectivity effects of the genome-wide significant psychosis variant in ZNF804A. Neuroimage 2011; 54: 2514-2523.
177. Paulus FM, Krach S, Bedenbender J, Pyka M, Sommer J, Krug A et al. Partialsupport for ZNF804A genotype-dependent alterations in prefrontal connectivity. Human Brain Mapping advance online publication, 31 October 2011; doi:10.1002/hbm.21434.
178. Lencz T, Szeszko PR, DeRosse P, Burdick KE, Bromet EJ, Bilder RM et al. A schizophrenia risk gene, ZNF804A, influences neuroanatomical and neurocognitive phenotypes. Neuropsychopharmacol Off Publication Am Coll Neuropsychopharmacol2010; 35: 2284-2291.
179. Erk S, Meyer-Lindenberg A, Schnell K, Opitz von Boberfeld C, Esslinger C, Kirsch P et al. Brain function in carriers of a genome-wide supported bipolar disorder variant. Arch Gen Psychiatry 2010; 67: 803-811.
180. Zhang Q, Shen Q, Xu Z, Chen M, Cheng L, Zhai J et al. The effects of CACNA1C gene polymorphism on spatial working memory in both healthy controls and patients with schizophrenia or bipolar disorder. Neuropsychopharmacology 2012; 37; 677-684.
181. Chow EW, Ho A, Wei C, Voormolen EH, Crawley AP, Bassett AS. Association of schizophrenia in 22q11.2 deletion syndrome and gray matter volumetric deficits in the superior temporal gyrus. Am J Psychiatry 2011; 168: 522-529.
182. Neul JL. Unfolding neurodevelopmental disorders: the mystery of developing connections. Nat Med 2011; 17: 1353-1355.
183. Insel TR. Rethinking schizophrenia. Nature 2010; 468: 187-193.
184. Wray NR, Yang J, Goddard ME, Visscher PM. The genetic interpretation of area under the ROC curve in genomic profiling. PLoS Genet 2010; 6: e1000864.
185. Wray NR, Goddard ME, Visscher PM. Prediction of individual genetic risk to disease from genome-wide association studies. Genome Res 2007; 17: 1520-1528.
186. Wray NR, Goddard ME, Visscher PM. Prediction of individual genetic risk of complex disease. Curr Opin Genet Dev 2008; 18: 257-263.
187. Arranz MJ, Rivera M, Munro JC. Pharmacogenetics of response to antipsychotics in patients with schizophrenia. CNS Drugs 2011; 25: 933-969.
188. Paul SM. Therapeutic antibodies for brain disorders. Sci Transl Med 2011; 3: 84ps20.
189. Muglia P. From genes to therapeutic targets for psychiatric disorders - what to expect? Curr Opin Pharmacol 2011; 11: 563-571.
190. Abbott A. Novartis to shut brain research facility. Nature 2011; 480: 161-162.
191. Freedman R, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A et al. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci USA 1997; 94: 587-592.
192. Leonard S, Gault J, Moore T, Hopkins J, Robinson M, Olincy A et al. Further investigation of a chromosome 15 locus in schizophrenia: Analysis of affected sibpairs from the NIMH Genetics Initiative. Am J Med Genet 1998; 81: 308-312.
193. Stephens SH, Franks A, Berger R, Palionyte M, Fingerlin TE, Wagner B et al. Multiple genes in the 15q13-q14 chromosomal region are associated with schizophrenia. Psychiatr Genet 2012; 22: 1-14.
194. Court J, Spurden D, Lloyd S, McKeith I, Ballard C, Cairns N et al. Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: Alpha-bungarotoxin and nicotine binding in the thalamus. J Neurochem 1999; 73: 1590-1597.
195. Martin LF, Kem WR, Freedman R. Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology 2004; 174: 54-64.
196. Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D et al. Proof-ofconcept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 2006; 63: 630-638.
197. Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 2008; 165: 1040-1047.
198. Tregellas JR, Tanabe J, Rojas DC, Shatti S, Olincy A, Johnson L et al. Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia. Biol Psychiatry 2011; 69: 7-11.
199. Williams DK, Wang J, Papke RL. Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: Advantages and limitations. Biochem Pharmacol 2011; 82: 915-930.
200. Green ED, Guyer MS. Charting a course for genomic medicine from base pairs to bedside. Nature 2011; 470: 204-213.
201. Ikeda M, Aleksic B, Kirov G, Kinoshita Y, Yamanouchi Y, Kitajima T et al. Copy number variation in schizophrenia in the Japanese population. Biol Psychiatry 2010; 67: 283-286.
202. Szatmari P, Paterson AD, Zwaigenbaum L, Roberts W, Brian J, Liu XQ et al. Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat Genet 2007; 39: 319-328.
203. Magri C, Sacchetti E, Traversa M, Valsecchi P, Gardella R, Bonvicini C et al. New copy number variations in schizophrenia. PLoS One 2010; 5: e13422.
204. Mulle JG, Dodd AF, McGrath JA, Wolyniec PS, Mitchell AA, Shetty AC et al. Microdeletions of 3q29 confer high risk for schizophrenia. Am J Hum Genet 2010; 87: 229-236.
205. Willatt L, Cox J, Barber J, Cabanas ED, Collins A, Donnai D et al. 3q29 microdeletion syndrome: clinical and molecular characterization of a new syndrome. Am J Hum Genet 2005; 77: 154-160.
206. Kirov G, Grozeva D, Norton N, Ivanov D, Mantripragada KK, Holmans P et al. Support for the involvement of large copy number variants in the pathogenesis of schizophrenia. Hum Mol Genet 2009; 18: 1497-1503.
207. Christian SL, Fantes JA, Mewborn SK, Huang B, Ledbetter DH. Large genomic duplicons map to sites of instability in the Prader-Willi/Angelman syndrome chromosome region (15q11-q13). Hum Mol Genet 1999; 8: 1025-1037.
208. Miller DT, Shen Y, Weiss LA, Korn J, Anselm I, Bridgemohan C et al. Microdeletion/duplication at 15q13.2q13.3 among individuals with features of autism and other neuropsychiatric disorders. J Med Genet 2009; 46: 242-248.
209. Sharp AJ, Mefford HC, Li K, Baker C, Skinner C, Stevenson RE et al. A recurrent 15q13.3 microdeletion syndrome associated with mental retardation and seizures. Nat Genet 2008; 40: 322-328.
210. Helbig I, Mefford HC, Sharp AJ, Guipponi M, Fichera M, Franke A et al. 15q13.3 microdeletions increase risk of idiopathic generalized epilepsy. Nat Genet 2009; 41: 160-162.
211. Ingason A, Kirov G, Giegling I, Hansen T, Isles AR, Jakobsen KD et al. Maternally derived microduplications at 15q11-q13: implication of imprinted genes in psychotic illness. Am J Psychiatry 2011; 168: 408-417.
212. Weiss LA, Shen Y, Korn JM, Arking DE, Miller DT, Fossdal R et al. Association between microdeletion and microduplication at 16p11.2 and autism. N Engl J Med 2008; 358: 667-675.
213. Fernandez BA, Roberts W, Chung B, Weksberg R, Meyn S, Szatmari P et al. Phenotypic spectrum associated with de novo and inherited deletions and duplications at 16p11.2 in individuals ascertained for diagnosis of autism spectrum disorder. J Med Genet 2010; 47: 195-203.
214. Ullmann R, Turner G, Kirchhoff M, Chen W, Tonge B, Rosenberg C et al. Array CGH identifies reciprocal 16p13.1 duplications and deletions that predispose to autism and/or mental retardation. Human Mutation 2007; 28: 674-682.
215. Chance PF, Alderson MK, Leppig KA, Lensch MW, Matsunami N, Smith B et al. DNA deletion associated with hereditary neuropathy with liability to pressure palsies. Cell 1993; 72: 143-151.